A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. METHODS: In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks. The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. Secondary end points included resolution of NASH and regression of fibrosis. RESULTS: A total of 247 patients underwent randomization, of whom 103 (42%) had type 2 diabetes mellitus and 188 (76%) had significant (moderate) or advanced fibrosis. The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs. placebo, 55% vs. 33%, P = 0.007; 800-mg dose vs. placebo, 48% vs. 33%, P = 0.07). The results favored both the 1200-mg and 800-mg doses of lanifibranor over placebo for resolution of NASH without worsening of fibrosis (49% and 39%, respectively, vs. 22%), improvement in fibrosis stage of at least 1 without worsening of NASH (48% and 34%, respectively, vs. 29%), and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% and 25%, respectively, vs. 9%). Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups. The dropout rate for adverse events was less than 5% and was similar across the trial groups. Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo. CONCLUSIONS: In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both have been tested successfully on phase II clinical trials, proving they are well-tolerated by patients and showing MASH resolution without worsening of fibrosis (165, 166).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [166]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most importantly, resolution of NASH without worsening of fibrosis (49% with 1200 mg Lanifibranor, vs. 39% with 800 mg vs. 22% Placebo), improvement in fibrosis of at least one stage without worsening of NASH (48% vs. 34% vs. 22%) and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% vs. 25% vs. 9%) all favored the study drug as compared to placebo.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pan-PPAR agonist lanifibranor demonstrated significant MASH resolution and fibrosis improvement in clinical trials, though it was associated with weight gain [3,136].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“Diarrhea, nausea, peripheral edema, anemia and weight gain were all seen more frequently in patients receiving Lanifibranor [59].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Finally and most recently the Pan‐PPAR agonist Lanifibranor reached the primary endpoint of a decrease in SAF‐A score of at least two points in a large Phase 2b Trial [59]—a dose‐dependent effect was seen with more patients achieving the primary endpoint with 1200 mg versus 800 mg.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 4×
“Increase in aminotransferase level§§ 3 (4) 5 (6) 1 (1)”
InfluentialSelf-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citationNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Self-citationFriedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Self-citation
Research works printed but not linked: 2
- Sanyal AJ, Anstee QM, Trauner M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (NASH). Hepatology 2020; 72: 67A-68A. abstract 90.
- Ratziu V, de Guevara L, Safadi R, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double- blind, placebo-controlled phase 2b trial. Nat Med (in press).
Cited by
Items 401–500 of 830
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH
Fraser, D. A., Harrison, S. A., & Schuppan, D. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159804 · Cited by 11
“efficacy in a Phase 2b study in subjects with NASH [19].”
BackgroundSelf-citationMetabolic-Associated Fatty Liver Disease in Childhood and Adolescence
Vespoli, C., Iqbal, A. M., Kabbany, M. N., & Radhakrishnan, K. R. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.02.001 · Cited by 13
NAFLDkb: A Knowledge Base and Platform for Drug Development against Nonalcoholic Fatty Liver Disease
Xu, T., Gao, W., Zhu, L., Chen, W., Niu, C., Yin, W., Ma, L., Zhu, X., Ling, Y., Gao, S., et al. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00395 · Cited by 11
Gut‐specific inhibition of PPARα as a novel approach of NAFLD treatment
Zhang, L., & Guo, G. L. (2022) · Hepatology · doi:10.1002/hep.32592 · Cited by 12
Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor
Sabatini, S., & Gastaldelli, A. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.003 · Cited by 11
Yanagisawa, H., Maeda, H., Noguchi, I., Tanaka, M., Wada, N., Nagasaki, T., Kobayashi, K., Kanazawa, G., Taguchi, K., Chuang, V. T. G., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103314 · Cited by 10
“Therapeutic agents for MASH are currently under study in phase II clinical trials, including TLR4 inhibitors [5], PPAR-α and PPAR-γ dual agonists [6] and acetyl CoA carboxylase inhibitors [9].”
BackgroundMitochondrial targeted therapies in MAFLD
Lai, S., Tang, D., & Feng, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151498 · Cited by 11
Ning, M., Lu, D., Liang, D., & Ren, P. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1513993 · Cited by 11
Wu, Z. Y., Wang, Z., Chang, X., Chen, X., Ding, Q., Fu, R., Chong, C., Tang, J., & Huang, C. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf403 · Cited by 10
“For fatty-liver disease, we benchmarked NeCTAR against Lan-ifibranor—a balanced pan-PPAR agonist now in phase III trials for MASH/NASH and rated most effective for body mass index (BMI) reduction in NAFLD [34, 35]—and with classical herbal formulas.”
Das, S., Agarwal, K., Kapoor, N., Lakhani, O., & Gupta, A. D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000935 · Cited by 10
Bempedoic acid directly binds and activates PPARα
Papa, C., Rose, A., Martin, H., Useini, A., Florian, G., Liao, L., Rodríguez‐Aguilera, J. R., Allo, P. V., Hoffmann, A., Tvardovskiy, A., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.12.018 · Cited by 10
Genetic Predisposition to MASLD: Potential for Therapeutic Management
Karapanagiotidi, F., Boutari, C., & Sinakos, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041933 · Cited by 10
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
Александровна, П. В., & Okovityi, S. V. (2026) · Biomedicines · doi:10.3390/biomedicines14040909 · Cited by 10
Tachi, K., Agyei-Nkansah, A. A., Atiase, Y., Forkuo, B., & Agyen-Frimpong, V. A. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002294 · Cited by 10
General Overview About the Current Management of Nonalcoholic Fatty Liver Disease
Ampuero, J. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01142-w · Cited by 10
“To date, obeticholic acid is the only drug approved for a different indication (primary biliary cholangitis) that has shown positive results in improving liver fibrosis in patients with NASH in a phase III trial [38], while other drugs such as lanifibranor (a peroxisome proliferator-activated receptor agonist) have sh…”
BackgroundYagai, T., & Nakamura, T. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1060244 · Cited by 13
Diagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease
Ganakumar, V., Halebidu, T., Goroshi, M., & Ghatnatti, V. (2024) · International journal of clinical metabolism and diabetes. · doi:10.1177/30502071231220779 · Cited by 10
Management of Cardiovascular Risk in the Non‑alcoholic Fatty Liver Disease Setting
Luque-Linero, P., & Castilla‐Guerra, L. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.19 · Cited by 14
Traconis, A. P. M., Uribe, M., & Barbero-Becerra, V. J. (2024) · Cells · doi:10.3390/cells13242055 · Cited by 11
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“An upcoming phase 3 trial (NATiV3, NCT04849728) is set to randomize approximately 1000 patients with NASH and advanced fibrosis [175,176].”
Guo, Z., Yao, Z., Huang, B., Wu, D., Li, Y., Chen, X., Lu, Y., Wang, L., & Lv, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112821 · Cited by 10
Zhi, Y., Dong, Y., Li, X., Zhong, W., Lei, X., Tang, J. T., & Mao, Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3846 · Cited by 10
“Additionally, weight gain is frequently observed in patients using PPAR agonists, which could be counterproductive in MASH treatment [31].”
Sun, Y., Yuan, X., Hu, Z., & Li, Y. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116730 · Cited by 10
Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502442 · Cited by 9
Self-citationZhong, H., Liu, C., Huang, Z., Tan, P., Chen, H., & Fu, W. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.02.003 · Cited by 10
Lee, B. K., Ghumman, U., Pedicone, L. D., Gómez-Aldana, A., & Lawitz, E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0337 · Cited by 11
Malandris, K., Charalampidis, K., Loomba, R. S., & Sinakos, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01621-w · Cited by 12
Self-citationReinson, T., Bilson, J., Childs, C. E., Buchanan, R. M., Targher, G., & Byrne, C. D. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002038 · Cited by 12
Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease
Weiskirchen, R., & Lonardo, A. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671694 · Cited by 9
Akuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., 疋田隼人, et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02408-2 · Cited by 10
“These include farnesoid X receptor agonists [108] (e.g., obeticholic acid), thyroid hormone receptor-β agonists [109] (e.g., resmeti-rom), and pan-PPAR agonists [110] (e.g., lanifibranor).”
Samuel, S., Abulawi, A., & Malik, R. (2023) · Gastroenterology Insights · doi:10.3390/gastroent14030018 · Cited by 10
Gato, S., García‐Fernández, V., Gil‐Gómez, A., Rojas, Á., Montero‐Vallejo, R., Múñoz‐Hernández, R., & Romero‐Gómez, M. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.26 · Cited by 10
“124 There are three types of PPAR nuclear receptors, namely PPARα, PPARδ and PPARγ, with PPARα being highly expressed in the liver.”
BackgroundSelf-citationLearnings From the Graveyard of Phase 2 and 3 Nonalcoholic Steatohepatitis Trials
Francque, S. M., Noureddin, M., & Krag, A. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.07.013 · Cited by 9
Self-citationMacrophage heterogeneity in liver fibrosis
Wang, W., Li, S., Liu, Y., Ding, X., Yang, Y., Chen, S., Cao, J., Tacke, F., Dong, W., & Lan, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639455 · Cited by 8
Sugihara, T. (2025) · Yonago acta medica · doi:10.33160/yam.2025.05.002 · Cited by 8
Fiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
Windell, D., Magness, A. J., Beyer, C., Thomaides-Brears, H. B., Larkin, S. J., Hobson, K., Aljabar, P., Fleming, K., Fryer, E., Kendall, T. J., et al. (2025) · Journal of Clinical Pathology · doi:10.1136/jcp-2025-210311 · Cited by 9
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 11
“These include the glucagon-like peptide-1 receptor agonist (GLP1RAs) semaglutide [58], the pan-PPAR agonist lanifibranor [59], the GLP1/glucagon co-agonist (survodutide) [60], and FGF21 analogues (efruxifermin and pegozafermin) [61,62].”
InfluentialSelf-citationNew Treatment Options for MASLD Patients with Type 2 Diabetes
Mega, A., Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026) · Life · doi:10.3390/life16020254 · Cited by 12
Liu, M., Ma, Y., Cheang, W. S., Su, Z., & Xu, S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.011 · Cited by 11
Li, F., Li, H., Juramt, D., Kou, K., Tacke, F., & Chen, L. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002343 · Cited by 11
Stéatose hépatique non alcoolique : diagnostic et traitement en 2022
Tagkou, N. M., & Goossens, N. (2023) · Schweizer Gastroenterologie · doi:10.1007/s43472-023-00091-9 · Cited by 13
Flavin, B. M. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.9-a.s1 · Cited by 14
Salidroside may target PPARα to exert preventive and therapeutic activities on NASH
Chu, X., Liu, S., Qu, B., Xin, Y., & Lu, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1433076 · Cited by 8
Innovative nanomedicine approaches for the management of nonalcoholic fatty liver disease
Li, L., Gao, W., Yao, F., Li, J., Sang, W., & Zhang, R. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113680 · Cited by 9
Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review
Castagneto‐Gissey, L., Bornstein, S. R., & Mingrone, G. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155721 · Cited by 8
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 9
Gastaldelli, A. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-569 · Cited by 9
Pieralice, S., Amendolara, R., Berna, V., Manganaro, G., Zurru, A., D’Onofrio, L., Risi, R., Alfonsi, M., Maddaloni, E., & Buzzetti, R. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s528569 · Cited by 10
“Therefore, insulin should be used cautiously in these patients, and alternative treatments with dual benefits on both glycemic control and liver health are preferred.”
Dijck, E. V., Laere, S. V., Logie, E., Timmermans, S., Fransén, E., Ibrahim, J., Kendall, T. J., Fallowfield, J. A., Mateiu, L. M., Libert, C., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01945-6 · Cited by 13
Self-citationTreatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease
Patel, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176060 · Cited by 7
“Compared with the placebo group, the percentage of patients who had a decrease of at least 2 points in the SAF score without worsening fibrosis was much higher in the 1200 mg lanifibranor group than those who took 800 mg of lanifibranor [32].”
InfluentialTincopa, M. A., Speliotes, E. K., Valenti, L. V. C., & Loomba, R. S. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050324-124753 · Cited by 8
Self-citationMASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues
Ha, S., Zhang, X., Lan-juan, L., & Yu, J. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.04.048 · Cited by 8
Shengir, M., Lebouché, B., Elgretli, W., Saeed, S., Ramanakumar, A. V., Giannakis, A., de Pokomandy, A., Cox, J., Costiniuk, C. T., Routy, J., et al. (2023) · HIV Medicine · doi:10.1111/hiv.13531 · Cited by 8
“Repeated CAP measurements are used as therapy markers in ongoing clinical trials of non-alcoholic steatohepatitis (NASH)-targeted therapies [13, 14].”
MethodSuk, F., Hsu, F.-Y., Hsu, M.-H., Chiu, W., Fang, C.-C., Chen, T.-L., & Liao, Y. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122327 · Cited by 7
Zhang, X., Wang, C., Min, R., Zhou, Q., Qi, Y., & Fan, J. (2024) · Nutrition Research · doi:10.1016/j.nutres.2024.03.002 · Cited by 7
Sabinari, I. W., Horakova, O., Čajka, T., Kleinova, V., Wieckowski, M. R., & Rossmeisl, M. (2024) · Physiological Research · doi:10.33549/physiolres.935396 · Cited by 7
Tan, Y., Qu, W., Zhao, J., Ma, Y., Zhang, Q., Gao, H., Zhen, Q., Wang, Y., Peng, Y., Liu, F., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101680 · Cited by 7
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Koullias, E., & Koskinas, J. S. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00564 · Cited by 8
The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies
Tapper, E. B., Fleming, C., Rendon, A., Fernandes, J. D. D. R., Johansen, P., Augusto, M., & Nair, S. (2022) · Gastro Hep Advances · doi:10.1016/j.gastha.2022.06.016 · Cited by 10
Meyer, E. L., Mesenbrink, P. G., Prospero, N. A. D., Pericàs, J. M., Glimm, E., Ratziu, V., Sena, E., König, F., & on behalf of the EU-PEARL NASH Investigators (2023) · PLoS ONE · doi:10.1371/journal.pone.0281674 · Cited by 7
“In particular, semaglutide demonstrated a 42 percentage point response rate increase in NASH resolution (endpoint 1) as compared to placebo [33] and lanifibranor demonstrated a 19 percentage point response rate increase in fibrosis improvement (endpoint 2) as compared to placebo [34].”
BackgroundSelf-citationvan Dijk, A. M., de Vries, M., El-Morabit, F., Bac, S. T., Mundt, M. W., van der Schuit, L. E., Hirdes, M. M., Kara, M., de Bruijne, J., van Meer, S., et al. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03417-2 · Cited by 7
“…years, promising short-term results in selected patient groups with MASLD have been reported for pharmacologic therapies of such as 7-ethyl chenodeoxycholic acid (Obet-icholic acid®) [36, 37], the pan-PPAR (peroxisome pro-liferator–activated receptor) agonist Lanifibranor [38] and semaglutide [39].”
BackgroundState-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Cho, Y., & Lee, Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.102 · Cited by 8
“NATIVE trial [35] Phase 2b doubleblind, randomized, placebo-controlled Lanifibranor: panPPAR agonist 1:1:1 Lanifibranor 1,200 mg Lanifibranor 800 mg Placebo 6 months (24 weeks) Noncirrhotic, highly active NASH (biopsy-proven) Decrease of at least 2 points in the SAF-A score without worsening of fibrosis Improved: Achi…”
MethodBrodosi, L., Petroni, M. L., & Marchesini, G. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2208746 · Cited by 7
“Only lanifibranor has so far achieved both targets in a six-month phase 2b trial without safety concerns [6]; waiting for more solid data, lifestyle treatment is the only approach systematically suggested by international guidelines [7].”
BackgroundEmerging synthetic drugs for the treatment of hepatic cirrhosis: a 2024 update
Fallowfield, J. A., & Ramos, M. J. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2341878 · Cited by 8
“Lanifibranor is an oral pan-peroxisome proliferator-activated receptor (PPAR) agonist that is the only drug in phase 3 that has shown efficacy against the dual histological endpoint of NASH resolution and fibrosis improvement (NATIVE; NCT03008070), albeit in noncirrhotic NASH [15].”
Gupta, N., & Singh, K. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10507-2 · Cited by 6
“…a pan-PPAR (peroxisome proliferator-activated receptor) agonist developed by Inventiva, demonstrated NASH resolution in 49% of patients compared to 27% in the placebo group in the NATIVE trial, with EMA clearance sought in 2024 and FDA approval expected by 2025, while (Francque et al. 2021).”
Olveira, A., Crespo, J., Ibáñez, L., Gallego‐Durán, R., Calleja, J. L., Aller, R., Sòria, A., Gómez‐Camarero, J., Martín‐Mateos, R., Benlloch, S., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.08.023 · Cited by 10
Self-citationHénin, G., Goffaux, A., Declerck, S., André‐Dumont, S., Pendeville, É., Valet, M., Lejeune, T. M., Dahlqvist, G., Loumaye, A., Schnabl, B., et al. (2025) · JCSM Communications · doi:10.1002/rco2.70012 · Cited by 6
Self-citationZahid, M., Lal, A., Almas, A., & Parkash, O. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01353-4 · Cited by 6
Uchida, M., Yamazaki, H., Han, S., Huang, B. Z., Ariyoshi, S., Hirayama, Y., Matsushita, S., Horitani, R., Wagner, R. J., & Heni, M. (2025) · Diabetes · doi:10.2337/db25-0629 · Cited by 6
Fu, R., Zhang, F., Fu, J., Li, Y., Zhu, X., Ding, Q., & Zhu, Y. Z. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.163 · Cited by 7
Zhang, Y., Wang, Y., Li, B., Li, X., Liu, C., Chen, Y., Cheng, T., Wang, D., Gu, X., Jiang, C., et al. (2026) · Advanced Science · doi:10.1002/advs.202519563 · Cited by 8
Dawn of an era of effective treatments for MAFLD
Gofton, C., & George, J. (2024) · Portal hypertension & cirrhosis · doi:10.1002/poh2.96 · Cited by 7
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 7
“…(1) the pan-PPAR agonist Lanifibranor, which has shown a positive dose-dependent improvement of steatohepatitis and fibrosis in a Phase 2B trial [294] (the phase III registrational trial is ongoing, although there are concerns regarding side effects) and (2) the dual PPARα/γ agonist…”
Koullias, E., Papavdi, M., Koskinas, J. S., Deutsch, M. J., & Thanopoulou, A. C. (2025) · Cureus · doi:10.7759/cureus.76716 · Cited by 13
Boursier, J., Hervé, H., Roux, M., Abdelmalek, M. F., Francque, S., Broqua, P., Junien, J., Abitbol, J., Huot-Marchand, P., Dzen, L., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.12.039 · Cited by 6
Self-citationComplexity of metabolic dysfunction–associated steatotic liver disease: State of the art review
Yeh, H., Lin, S. J., Shen, H., Li, T., Tsai, H., Yang, Y., Lin, H.-C., & Hou, M. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001254 · Cited by 6
“48 The study reported that 49% of 1200-mg group, 39% of 800-mg group, and 22% of placebo group of patients with NASH patients had reduced their NASH severity without worsening of fibrosis; 48% of 1200-mg group, 34% of 800-mg group, and 29% of placebo group of patients with NASH patients had…”
Yu, M., Ren, X. D., Li, R., Shen, W., Zhao, B., Li, Y., Zhang, X., Cui, X., Zhu, J., Zhang, X., et al. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100065 · Cited by 6
PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD
Lonardo, A., & Weiskirchen, R. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100590 · Cited by 7
Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma
Akl, M. G., & Widenmaier, S. B. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1089124 · Cited by 9
“Patients with active NASH given Lanifibranor showed a significant reduction in steatosis and fibrosis when compared to placebo group and had improved liver enzymes and lipid profile (Francque et al., 2021).”
BackgroundSemaglutide in NASH-related cirrhosis: too late to the party?
Bril, F. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00069-9 · Cited by 7
Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1
Yin, Y.-H., Sang, L.-X., & Chang, B. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i48.6235 · Cited by 6
Laghezza, A., Cerchia, C., Genovese, M., Montanari, R., Capelli, D., Wackerlig, J., Simić, S., Falbo, E., Pecora, L., Leuci, R., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116567 · Cited by 7
Patients with chronic liver diseases are at risk for diabetes even before development of cirrhosis
Bale, G., Clarembeau, F., Stärkel, P., Dahlqvist, G., Horsmans, Y., & Lanthier, N. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102428 · Cited by 7
Self-citationTreating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach
Li, X., Rao, Z., Hu, W., Lu, W., & Luo, Y. (2024) · Obesity Reviews · doi:10.1111/obr.13861 · Cited by 9
Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2441865 · Cited by 8
“Additionally, peroxisome proliferator-activated receptor (PPAR) agonists like pioglitazone and lanifibranor have been investigated for the MASH treatment [23].”
Self-citationde Souza, M. H. G., Amaral, M. J. M., Lima, L. C. V., & Villela‐Nogueira, C. A. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18498 · Cited by 6
Lei, K., Chen, Y., Wu, J., Lin, Y., Bai, Y., Cao, H., Che, Q., Guo, J., & Su, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142275 · Cited by 9
PPARɑ variant V227A reduces plasma triglycerides through enhanced lipoprotein lipolysis
Uchiyama, L. F., Ordonez, G. P. M., Pham, K. T., Kennelly, J. P., Rodríguez, M. L., Tran, L., Tontonoz, P., & Nguyen, A. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100806 · Cited by 6
“Given the use of PPAR agonists in the management of clinical hyper-triglyceridemia and in clinical trials for MASLD-associated steatohepatitis and fibrosis (6), understanding the molecular regulation of PPAR ɑ transcriptional activity may provide opportunities for control of metabolic dysfunction.”
Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease
Cho, Y. E., Kwon, Y. S., & Hwang, S. (2022) · Liver Research · doi:10.1016/j.livres.2022.06.001 · Cited by 7
Imamura, T., & Kinugawa, K. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0277-22 · Cited by 6
“The pan-peroxisome proliferator-activated receptor agonist Lanifibranor was recently demonstrated to improve NAFLD in a phase II trial (9).”
BackgroundLuo, W., Gu, Y., Fu, S., Wang, J., Zhang, J., & Wang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115762 · Cited by 7
Tuffs, C., Dupovac, M., Richter, K., Holten, S., Schaschinger, T., Marg, O., Poljo, A., Tasdemir, A. N., Harnoss, J. M., Billeter, A. T., et al. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.10.018 · Cited by 5
Warda, F., Batch, J., Graham, L., Haas, M. J., & Mooradian, A. D. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2025.159599 · Cited by 5
Briand, F., Dubroca, C., Wettstein, G., Grasset, E., Breyner, N. M., Bigot, C., Assaly, R., Broqua, P., & Sulpice, T. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177945 · Cited by 6
Self-citationLuong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5
Li, N., Wu, S., Li, X., Yan, M., Ding, Y., Zhang, L., Brenner, D. A., Liu, X., & Kisseleva, T. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.06.012 · Cited by 6
Kumar, A. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.1058 · Cited by 7
Kamrul-Hasan, A. B. M., Borozan, S., Jena, S., Nagendra, L., Dutta, D., Bhattacharya, S., Islam, M. S., & Pappachan, J. M. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.110709 · Cited by 7
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2566258 · Cited by 6
“Longer-duration trials are warranted to evaluate the sustained efficacy and safety profile of lanifibranor [38].”
Self-citation
Metadata
- Authors
- Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., Lanthier, N., Alkhouri, N., Moreno, C., Schattenberg, J. M., Stefanova-Petrova, D., Vonghia, L., Rouzier, R., Guillaume, M., Hodge, A., Romero-Gómez, M., Huot-Marchand, P., Baudin, M., Richard, M.-P., Abitbol, J.-L., Broqua, P., Junien, J.-L., & Abdelmalek, M. F.
- Affiliations
- Cliniques Universitaires Saint-Luc (BE)
- From Antwerp University Hospital and the Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp (S.M.F., L.V.), and Service d’Hépato-Gastroentérologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (N.L.) and Cliniques Universitaires de Bruxelles–Hôpital Erasme, Université Libre de Bruxelles (C.M.), Brussels — all in Belgium; the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom (P. Bedossa, Q.M.A.); Pitie–Salpétriêre Hospital, Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris (V.R.), Centre Hospitalier Universitaire Rangueil, Toulouse (M.G.), and Inventiva Pharma, Daix (P.H.-M., M.B., M.-P.R., J.-L.A., P. Broqua, J.-L.J.) — all in France; the Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy (E.B.); Virginia Commonwealth University, Richmond (A.J.S.); the University of California San Diego, La Jolla (R.L.); Pinnacle ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1547-1558
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3207086349
- Cited by
- 801
- References
- 33
- Citations by year
- 2026: 171 · 2025: 197 · 2024: 156 · 2023: 150 · 2022: 119 · 2021: 7
- FWCI
- 77.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc-nd)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Inventiva Pharma S.A., Daix, France
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- lanifibranor, nonalcoholic steatohepatitis, liver fibrosis regression, NASH resolution, type 2 diabetes, dose comparison, liver enzymes, PPAR agonists, fibrosis stage
- MeSH terms
- Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Sulfonamides, Body Mass Index, Peroxisome Proliferator-Activated Receptors, Benzothiazoles, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.